These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30291127)

  • 1. A Rethink for IO Biomarkers.
    Cancer Discov; 2018 Nov; 8(11):1342. PubMed ID: 30291127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Status of Immune Oncology: Challenges and Opportunities.
    Cesano A; Marincola FM; Thurin M
    Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
    Wilkinson RW; Leishman AJ
    Front Immunol; 2018; 9():1082. PubMed ID: 29910800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
    Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
    Front Immunol; 2019; 10():924. PubMed ID: 31134058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDL-1/PD1 inhibitors: antibody or antinobody?
    Aoun F; Rassy EE; Assi T; Kattan J
    Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
    Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
    World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
    Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Masterful Antibodies: Checkpoint Blockade.
    Lonberg N; Korman AJ
    Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
    Fortis SP; Kotsakis A; Le Tourneau C; Tsitsilonis OE; Georgoulias V; Baxevanis CN
    Cancer Immunol Immunother; 2019 Aug; 68(8):1391-1400. PubMed ID: 31309256
    [No Abstract]   [Full Text] [Related]  

  • 13. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.
    Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Gelber RD; Goldhirsch A
    Ann Oncol; 2019 Apr; 30(4):653-655. PubMed ID: 30698647
    [No Abstract]   [Full Text] [Related]  

  • 16. Combining conventional therapy with immunotherapy: A risky business?
    Coosemans A; Vankerckhoven A; Baert T; Boon L; Ruts H; Riva M; Blagden S; Delforge M; Concin N; Mirza MR; Ledermann JA; du Bois A; Vergote I
    Eur J Cancer; 2019 May; 113():41-44. PubMed ID: 30965214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
    Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
    Shevchenko I; Bazhin AV
    Front Immunol; 2018; 9():1816. PubMed ID: 30131808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.